Acción SENSI SENSIDOSE AB
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Sensidose AB

Acciones

SENSI

SE0017232671

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Updated recommendation by the nomination committee of Navamedic ASA
Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag
Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer
Navamedic ASA (OB:NAVA) completed the acquisition of Sensidose AB.
EQL Pharma AB publishes the final outcome in public takeover offer. As a result of the shareholder dynamics and other circumstances the Board also announces its intention to sell its holdings.
EQL Pharma AB cancelled the acquisition of all the remaining stake in Sensidose AB.
Navamedic ASA Q1 2023: Another strong quarter
Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag
Sensidose AB Reports Earnings Results for the First Quarter Ended March 31, 2023
Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag
Navamedic increases the consideration to SEK 0.60 in cash per warrant of series TO 1 in its unconditional offer to the warrant holders in Sensidose Aktiebolag
EQL Pharma extends the unconditional offer to include warrants series TO 1 and publishes a supplementary offer document regarding EQL Pharma's offer to the shareholders of Sensidose
Navamedic ASA expands its offer to include warrants of series TO 1 issued by Sensidose Aktiebolag at a price of SEK 0.38 in cash per warrant of series TO 1
Correction: Navamedic publishes a supplement to the offer document regarding the cash offer to the shareholders of Sensidose Aktiebolag
Navamedic publishes a supplement to the offer document regarding the recommended cash offer to the shareholders of Sensidose Aktiebolag
Offer document regarding EQL Pharma's offer to the shareholders of Sensidose Aktiebolag published
Sweden’s EQL Pharma Increases Bid for Sensidose
EQL Pharma AB announces a revised unconditioned cash offer of SEK 8.40 per share to the shareholders of Sensidose Aktiebolag
Navamedic Raises Takeover Offer for Sensidose, Agrees to Buy 57% Stake
Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción SENSI
  4. Noticias Sensidose AB
  5. Otros idiomas